Bristol-Myers Squibb Shares Rise After Analyst Upgrade SAnd Positive Pipeline Outlook
Bristol-Myers Squibb Shares Rise After Analyst Upgrade SAnd Positive Pipeline Outlook
The analyst expressed confidence that Milvexian, a drug in development for atrial fibrillation, could achieve positive results in non-inferiority trials, further supporting the company's growth prospects. He also noted improved visibility on Bristol-Myers Squibb's financials, driven by positive momentum from recent product launches and growing clarity on cost control measures. As a result, he raised his earnings-per-share projections, expecting the company to reach EPS floor of $6 in the near future.Bristol-Myers Squibb Inc. (NYSE:BMY) shares saw are trading higher Monday. Jefferies analyst, Akash Tewari, raised his rating on the stock from Hold to Buy and increased the price target from $63 to $70. Here's what you need to know.
施貴寶公司（紐交所：BMY）的股票在週一交易上漲。Jefferies的分析師Akash Tewari將該股票的評級從持有提高到買入，並將價格目標從63美元提高到70美元。以下是您需要了解的信息。
What To Know: The analyst's upgrade comes after increased confidence in several aspects of Bristol-Myers Squibb's business, particularly its pipeline and upcoming product launches. Tewari highlighted three key reasons for the upgrade.
需要了解的事項：該分析師的升級是基於對施貴寶業務多個方面的信心增強，特別是其管道和即將推出的產品。Tewari強調了升級的三個關鍵原因。
Tewari believes Cobenfy (KarXT), a treatment for schizophrenia and bipolar disorder, is on track to become a $10 billion-plus drug. He is bullish on the drug's launch in schizophrenia, as well as its potential in treating Alzheimer's psychosis and bipolar disorder. He expects strong sales growth in the coming years, with a 2025 forecast of $215 million, significantly above consensus estimates.
Tewari認爲Cobenfy（KarXT），一種治療精神分裂症和雙相障礙的藥物，有望成爲一個超過100億美元的藥物。他對該藥物在精神分裂症中的推出持看好態度，以及其在治療阿爾茨海默病精神病和雙相障礙方面的潛力。他預計在未來幾年將實現強勁的銷售增長，預計2025年的銷量爲21500萬美元，遠高於市場共識預期。
The analyst expressed confidence that Milvexian, a drug in development for atrial fibrillation, could achieve positive results in non-inferiority trials, further supporting the company's growth prospects. He also noted improved visibility on Bristol-Myers Squibb's financials, driven by positive momentum from recent product launches and growing clarity on cost control measures. As a result, he raised his earnings-per-share projections, expecting the company to reach EPS floor of $6 in the near future.
該分析師表示信心，認爲正開發的Milvexian，一種用於房顫的藥物，能夠在非劣效性試驗中取得積極結果，進一步支持公司的增長前景。他還指出，施貴寶的財務狀況得到了改善的可見性，這得益於近期產品推出帶來的積極動力以及對成本控制措施的日益清晰。因此，他提高了每股收益的預期，預計公司將在不久的將來達到每股收益6美元的底線。
Additionally, the company's ongoing collaboration with Immatics N.V. remains intact, despite the recent termination of other partnership agreements, including the allogeneic and opt-in collaborations with BMS. While this move reflects ongoing portfolio prioritization efforts, the termination does not require Bristol-Myers Squibb to refund any of the upfront payments.
此外，儘管最近終止了與BMS的其他合作協議，包括異體和期權合作，公司的與Immatics N.V.的持續合作仍然完好。雖然這一舉動反映了持續的投資組合優先排序工作，但終止並不要求施貴寶退還任何預付款項。
With a new price target of $70, Jefferies sees upside potential in Bristol-Myers Squibb's stock.
在70美元的新價格目標下，Jefferies認爲施貴寶的股票存在上行潛力。
BMY Price Action: Bristol-Myers Squibb shares were up 0.14% at $55.86 at the time of writing, according to Benzinga Pro.
BMY股票走勢：根據Benzinga Pro的信息，施貴寶的股票在撰寫時上漲0.14%，報55.86美元。
- IonQ, Quantum Computing And Rigetti Computing Shares Are Soaring Monday: What's Going On?
- IonQ, 量子計算概念和Rigetti Computing的股票在星期一飆升：發生了什麼？
Image Via Shutterstock.
圖片來自Shutterstock。
譯文內容由第三人軟體翻譯。